23andMe, headquartered in Sunnyvale, CA, has reached an exciting milestone by raising $861,000,000 in its latest funding round. Since its founding in 2006, the company has been a pioneer in consumer genetics, driven by its mission to help people access, understand, and benefit from the human genome. As the only company with multiple FDA authorizations for genetic health risk reports, 23andMe has consistently demonstrated its commitment to safeguarding and empowering its customers. Integral to its success is the world’s largest crowdsourced platform for genetic research—an initiative that sees 80 percent of its customers choosing to participate—fueling over 180 scientific publications that deepen our understanding of the genetic underpinnings of various diseases, conditions, and traits.
The newly raised capital will be strategically invested to expand the company’s research platform and accelerate the 23andMe Therapeutics group’s cutting-edge drug discovery programs. With plans to explore innovative treatments across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, this funding marks a significant step forward in translating genetic insights into effective therapies. Moreover, this financial boost will support the enhancement of the company’s robust infrastructure, ensuring that 23andMe continues to lead in consumer genetic innovation while contributing invaluable data to the scientific community.
Recognized as one of the San Francisco Chronicle’s Top Workplaces and Comparably’s Best Places to Work, 23andMe’s culture of excellence is further highlighted by the leadership of CEO Anne Wojcicki—an executive celebrated as one of Glassdoor’s Top CEOs and one of Comparably’s Best CEOs for Women. This funding announcement not only reaffirms investor confidence but also sets the stage for 23andMe’s next era of groundbreaking advancements in human genetics.
